Abstract
Constitutional mismatch repair deficiency syndrome should be considered in children with acute leukemia and characteristic skin lesions.
The high mutation burden of CMMRD-related cancers contributes to treatment resistance, necessitating individualized treatment strategies.
MeSH terms
-
Antibodies, Bispecific / administration & dosage
-
Antibodies, Bispecific / therapeutic use
-
Antineoplastic Agents, Immunological / administration & dosage
-
Antineoplastic Agents, Immunological / therapeutic use
-
Bone Marrow / abnormalities
-
Bone Marrow / metabolism*
-
Bone Marrow / pathology
-
Brain Neoplasms / complications
-
Brain Neoplasms / genetics*
-
Child
-
Colorectal Neoplasms / complications
-
Colorectal Neoplasms / genetics*
-
Fatal Outcome
-
Humans
-
Inotuzumab Ozogamicin / administration & dosage
-
Inotuzumab Ozogamicin / therapeutic use
-
Male
-
Mutation / genetics
-
Neoplastic Syndromes, Hereditary / complications
-
Neoplastic Syndromes, Hereditary / genetics*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
Substances
-
Antibodies, Bispecific
-
Antineoplastic Agents, Immunological
-
blinatumomab
-
Inotuzumab Ozogamicin